This is the authors' abstract. We don't add key points for this paper.
Uromonitor represents a reliable tool in the detection of NMIBC recurrence in patients undergoing routine surveillance, regardless of stage and grade. To our knowledge, this is the largest single-center study assessing Uromonitor's performance, thus validating its usefulness in clinical practice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ramos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: